NovoCure (NASDAQ:NVCR) Shares Down 7.7% Following Insider Selling

NovoCure Limited (NASDAQ:NVCR) shares traded down 7.7% on Friday following insider selling activity. The company traded as low as $13.19 and last traded at $13.1290. 445,392 shares changed hands during trading, a decline of 80% from the average session volume of 2,190,604 shares. The stock had previously closed at $14.23.

Specifically, Chairman William F. Doyle sold 71,887 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total value of $933,093.26. Following the transaction, the chairman owned 328,397 shares of the company’s stock, valued at approximately $4,262,593.06. This trade represents a 17.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Mukund Paravasthu sold 43,246 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $13.77, for a total transaction of $595,497.42. Following the transaction, the chief operating officer owned 72,832 shares of the company’s stock, valued at $1,002,896.64. This represents a 37.26% decrease in their position. The SEC filing for this sale provides additional information. In other news, COO Mukund Paravasthu sold 5,377 shares of NovoCure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $71,567.87. Following the completion of the sale, the chief operating officer owned 116,078 shares in the company, valued at approximately $1,544,998.18. This trade represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVCR. Wedbush restated a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a report on Thursday, January 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Finally, HC Wainwright raised their target price on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.93.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

NovoCure Stock Performance

The company has a market cap of $1.48 billion, a P/E ratio of -10.69 and a beta of 0.71. The company has a quick ratio of 1.50, a current ratio of 2.90 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $12.74 and a 200-day moving average of $12.71.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.19. The firm had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.61) EPS. As a group, sell-side analysts anticipate that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Hedge Funds Weigh In On NovoCure

Several institutional investors and hedge funds have recently modified their holdings of NVCR. Empowered Funds LLC purchased a new position in shares of NovoCure in the fourth quarter valued at approximately $33,000. SJS Investment Consulting Inc. acquired a new stake in shares of NovoCure in the 3rd quarter worth $41,000. Kestra Advisory Services LLC purchased a new position in shares of NovoCure during the 4th quarter worth $49,000. Larson Financial Group LLC raised its stake in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of NovoCure in the 2nd quarter valued at $88,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.